Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0LM2K
|
|||
| Former ID |
DNC009965
|
|||
| Drug Name |
2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
|
|||
| Synonyms |
CHEMBL566511; 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16O4S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC=C(C=C2)CCS(=O)(=O)CC(=O)O
|
|||
| InChI |
1S/C16H16O4S/c17-16(18)12-21(19,20)11-10-13-6-8-15(9-7-13)14-4-2-1-3-5-14/h1-9H,10-12H2,(H,17,18)
|
|||
| InChIKey |
PPYPHJNYICUMPA-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-12 (MMP-12) | Target Info | Inhibitor | [1] |
| Matrix metalloproteinase-13 (MMP-13) | Target Info | Inhibitor | [1] | |
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Plasminogen activating cascade | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| WikiPathways | Endochondral Ossification | |||
| Activation of Matrix Metalloproteinases | ||||
| Oncostatin M Signaling Pathway | ||||
| AGE/RAGE pathway | ||||
| Matrix Metalloproteinases | ||||
| TGF beta Signaling Pathway | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.